Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)

Conditions

• Non-Traumatic Subarachnoid Hemorrhage

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Metoprolol — DRUG
  Metoprolol Dosing: Metoprolol Injection (instructions: 5mg, once) Metoprolol Tab (25mg PO, q12 hours, timed to start 1hr after Metoprolol Injection, 6 doses) If unable to take PO medication, Metoprolol Injection (instructions, 5mg q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria
• Placebo — DRUG
  Placebo Dosing: Placebo Injection (instructions: 5mL NS, once) Placebo Tab (1 tab PO, q12 hours, timed to start 1hr after placebo injection, 6 doses) If unable to take PO medication, Placebo Injection (instructions, 5mL q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria

Study Details

To determine the effect of early metoprolol administration after non-traumatic subarachnoid hemorrhage (SAH).

Key Dates

Start date

Sep 23, 2024

Status verified

Nov 2024

Primary completion

Sep 30, 2026

Completion

Sep 30, 2029

Study Design

Enrollment

20 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Metoprolol (Beta-adrenergic blockade)
  Patients will receive metoprolol during the first 72-hours of hospitalization after non-traumatic SAH.
• Placebo Comparator: Placebo
  Patients will receive placebo during the first 72-hours of hospitalization after non-traumatic SAH.

Primary Outcome Measure

Delta QTc length [ Time Frame: 7 days ]

Central Contacts

• Madeleine Puissant, MD, PhD
  2076613660
  [email protected]
• Christine Lord
  [email protected]

Locations (1)

Find similar trials in Portland, ME